News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Claims Iran Requested Delay in Strikes; US Stocks Post Largest Drop Since US-Iran Conflict Began; Apple Opens Siri to External AI (March 27, 2026)2US-Iran Tensions Latest: Diplomatic Deadlock Drives Market Fluctuations as Trump Prolongs Suspension of Attacks on Energy Facilities3Bitcoin gained 655% the last time this supply in profit metric dropped to 50%
A8 (Ancient8) 24-hour volatility reaches 43.8%: trading volume surges 171.7% driving price rebound
Bitget Pulse·2026/03/27 11:26
Anthropic's Disclosure: A $285 Billion Cash Flow Event
101 finance·2026/03/27 11:21
Nissin Foods Reduces Dividend Despite 64.9% Profit Jump: Could Investors Be Overlooking a Strategic Opportunity?
101 finance·2026/03/27 11:18
ONUS Breakdown: Examining the Flow Behind a Multi-Billion Dollar Liquidity Crisis
101 finance·2026/03/27 11:18
Nortech’s Q4 Earnings Squeeze: Margin Gains Outpace Revenue Decline—Is This a Sell-the-News Play?
101 finance·2026/03/27 11:15
Immersion Posts $13.7M Loss Despite 59% Revenue Surge
101 finance·2026/03/27 11:12
XRP Price Hits Shocking Low of $1.33 as Investors Yank $57M from XRP ETFs Before SEC Deadline Today
Tipranks·2026/03/27 11:12
Argan (AGX) Jumps 10.7% — Yet Trading Activity Stays Low
101 finance·2026/03/27 11:09
Flash
11:24
BMO Capital Markets recently announced an adjustment to its stock rating for Terns Pharmaceuticals, Inc., downgrading it from "Outperform" to "Market Perform."At the same time, the institution lowered the target stock price from the previous $54 to $53. This rating adjustment reflects the market's cautious attitude toward the company's near-term development prospects. Although the target price was only slightly reduced by $1, the change in rating may affect investor confidence in the stock. Pharmaceutical stocks have recently been generally under dual pressure from R&D progress and market competition. Analysts pointed out that attention should be paid to the company's subsequent clinical trial data and commercialization process.
11:24
ADMA Biologics Inc recently responded to a short-selling report, firmly stating that the report presents a serious distortion and confusion regarding the actual efficacy and competitive position of its product Asceniv in the intravenous immunoglobulin (IVIG) market.The company emphasized that the allegations in the report fail to accurately reflect the clinical value and market positioning of Asceniv.
11:23
ADMA Biologics Inc (ADMA Biologics) has issued an official statement regarding the recent report released by Culper ResearchThe company made it clear that the allegations in the report are unfounded, misleading, and untrue. ADMA Biologics firmly denies all false statements in the report and is committed to maintaining the integrity of its operations as well as its commitment to shareholders and patients.
News